<DOC>
	<DOCNO>NCT00732602</DOCNO>
	<brief_summary>The purpose study determine whether Glucose-dependent Insulinotropic Polypeptide ( GIP ) Glucagon Like Peptide 2 ( GLP-2 ) affect secretion Glucagon pancreas patient type 1 diabetes mellitus .</brief_summary>
	<brief_title>The Effects GIP GLP-2 Secretion Glucagon Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Caucasians 18 year type 1 diabetes ( WHO criteria ) Arginine test without rise plasma Cpeptide Normal blood Hemoglobin Informed consent Liver disease Diabetic nephropathy Treatment medication unpausable 12 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Glucagon</keyword>
	<keyword>Glucose-dependent Insulinotropic Polypeptide</keyword>
	<keyword>Glucagon-Like peptide 2</keyword>
</DOC>